Kidney damage and associated risk factors in rural and urban sub-Saharan Africa (AWI-Gen): a cross-sectional population study.
Journal
The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
17
04
2019
revised:
26
09
2019
accepted:
01
10
2019
entrez:
12
11
2019
pubmed:
12
11
2019
medline:
28
5
2020
Statut:
ppublish
Résumé
Rapid epidemiological health transitions occurring in vulnerable populations in Africa that have an existing burden of infectious and non-communicable diseases predict an increased risk and consequent prevalence of kidney disease. However, few studies have characterised the true burden of kidney damage and associated risk factors in Africans. We investigated the prevalence of markers for kidney damage and known risk factors in rural and urban settings in sub-Saharan Africa. In this cross-sectional population study (Africa Wits-International Network for the Demographic Evaluation of Populations and their Health Partnership for Genomic Studies [AWI-Gen]), we recruited unrelated adult participants aged 40-60 years from four rural community research sites (Nanoro, Burkina Faso; Navrongo, Ghana; Agincourt and Dikgale, South Africa), and two urban community research sites (Nairobi, Kenya; and Soweto, South Africa). Participants were identified and selected using random sampling frames already in use at each site. Participants completed a lifestyle and medical history questionnaire, had anthropometric and blood pressure measurements taken, and blood and urine samples were collected. Markers of kidney damage were defined as low estimated glomerular filtration rate (eGFR; <60 mL/min per 1·73 m Between August, 2013, and August, 2016, we recruited 10 702 participants, of whom 8110 were analysable. 4120 (50·8%) of analysable participants were male, with a mean age of 49·9 years (SD 5·8). Age-standardised population prevalence was 2·4% (95% CI 2·1-2·8) for low eGFR, 9·2% (8·4-10·0) for albuminuria, and 10·7% (9·9-11·7) for chronic kidney disease, with higher prevalences in South African sites than in west African sites (14·0% [11·9-16·4] in Agincourt vs 6·6% [5·5-7·9] in Nanoro). Women had a higher prevalence of chronic kidney disease (12·0% [10·8-13·2] vs 9·5% [8·3-10·8]) and low eGFR (3·0% [2·6-3·6] vs 1·7% [1·3-2·3]) than did men, with no sex-specific differences for albuminuria (9·9% [8·8-11·0] vs 8·4% [7·3-9·7]). Risk factors for kidney damage were older age (relative risk 1·04, 95% CI 1·03-1·05; p<0·0001), hypertension (1·97, 1·68-2·30; p<0·0001), diabetes (2·22, 1·76-2·78; p<0·0001), and HIV (1·65, 1·36-1·99; p<0·0001); whereas male sex was protective (0·85, 0·73-0·98; p=0·02). Regional differences in prevalence and risks of chronic kidney disease in sub-Saharan Africa relate in part to varying stages of sociodemographic and epidemiological health transitions across the area. Public health policy should focus on integrated strategies for screening, prevention, and risk factor management in the broader non-communicable disease and infectious diseases framework. National Human Genome Research Institute, Office of the Director, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Environmental Health Sciences, the Office of AIDS Research, and National Institute of Diabetes and Digestive and Kidney Diseases, all of the National Institutes of Health, and the South African Department of Science and Technology.
Sections du résumé
BACKGROUND
Rapid epidemiological health transitions occurring in vulnerable populations in Africa that have an existing burden of infectious and non-communicable diseases predict an increased risk and consequent prevalence of kidney disease. However, few studies have characterised the true burden of kidney damage and associated risk factors in Africans. We investigated the prevalence of markers for kidney damage and known risk factors in rural and urban settings in sub-Saharan Africa.
METHODS
In this cross-sectional population study (Africa Wits-International Network for the Demographic Evaluation of Populations and their Health Partnership for Genomic Studies [AWI-Gen]), we recruited unrelated adult participants aged 40-60 years from four rural community research sites (Nanoro, Burkina Faso; Navrongo, Ghana; Agincourt and Dikgale, South Africa), and two urban community research sites (Nairobi, Kenya; and Soweto, South Africa). Participants were identified and selected using random sampling frames already in use at each site. Participants completed a lifestyle and medical history questionnaire, had anthropometric and blood pressure measurements taken, and blood and urine samples were collected. Markers of kidney damage were defined as low estimated glomerular filtration rate (eGFR; <60 mL/min per 1·73 m
FINDINGS
Between August, 2013, and August, 2016, we recruited 10 702 participants, of whom 8110 were analysable. 4120 (50·8%) of analysable participants were male, with a mean age of 49·9 years (SD 5·8). Age-standardised population prevalence was 2·4% (95% CI 2·1-2·8) for low eGFR, 9·2% (8·4-10·0) for albuminuria, and 10·7% (9·9-11·7) for chronic kidney disease, with higher prevalences in South African sites than in west African sites (14·0% [11·9-16·4] in Agincourt vs 6·6% [5·5-7·9] in Nanoro). Women had a higher prevalence of chronic kidney disease (12·0% [10·8-13·2] vs 9·5% [8·3-10·8]) and low eGFR (3·0% [2·6-3·6] vs 1·7% [1·3-2·3]) than did men, with no sex-specific differences for albuminuria (9·9% [8·8-11·0] vs 8·4% [7·3-9·7]). Risk factors for kidney damage were older age (relative risk 1·04, 95% CI 1·03-1·05; p<0·0001), hypertension (1·97, 1·68-2·30; p<0·0001), diabetes (2·22, 1·76-2·78; p<0·0001), and HIV (1·65, 1·36-1·99; p<0·0001); whereas male sex was protective (0·85, 0·73-0·98; p=0·02).
INTERPRETATION
Regional differences in prevalence and risks of chronic kidney disease in sub-Saharan Africa relate in part to varying stages of sociodemographic and epidemiological health transitions across the area. Public health policy should focus on integrated strategies for screening, prevention, and risk factor management in the broader non-communicable disease and infectious diseases framework.
FUNDING
National Human Genome Research Institute, Office of the Director, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Environmental Health Sciences, the Office of AIDS Research, and National Institute of Diabetes and Digestive and Kidney Diseases, all of the National Institutes of Health, and the South African Department of Science and Technology.
Identifiants
pubmed: 31708144
pii: S2214-109X(19)30443-7
doi: 10.1016/S2214-109X(19)30443-7
pmc: PMC7033368
mid: NIHMS1558789
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1632-e1643Subventions
Organisme : FIC NIH HHS
ID : K43 TW010698
Pays : United States
Organisme : NHGRI NIH HHS
ID : U54 HG006938
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Références
Nephrol Dial Transplant. 2010 Jul;25(7):2178-87
pubmed: 20100724
Menopause. 2014 Nov;21(11):1225-33
pubmed: 24736199
Nephron. 2018;139(4):313-318
pubmed: 29791905
J Am Soc Nephrol. 2015 Nov;26(11):2882-90
pubmed: 25788523
Am J Kidney Dis. 2016 Nov;68(5):743-751
pubmed: 27555103
Lancet Glob Health. 2014 Mar;2(3):e174-81
pubmed: 25102850
Glob Health Action. 2018;11(sup2):1507133
pubmed: 30259792
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
Glob Heart. 2017 Jun;12(2):81-90
pubmed: 28302553
Lancet Infect Dis. 2018 Nov;18(11):e362-e367
pubmed: 29980383
Int J Epidemiol. 2007 Jun;36(3):504-11
pubmed: 17355979
Soc Indic Res. 2017;133(3):1047-1073
pubmed: 28931968
Kidney Int. 2016 Jun;89(6):1363-71
pubmed: 27165829
PLoS One. 2015 Apr 17;10(4):e0124506
pubmed: 25886472
BMC Nephrol. 2013 Apr 02;14:75
pubmed: 23547953
BMC Nephrol. 2009 Jul 21;10:18
pubmed: 19622160
Adv Chronic Kidney Dis. 2014 Sep;21(5):426-33
pubmed: 25168832
Clin Chem. 2008 Jul;54(7):1197-202
pubmed: 18487286
Am J Physiol Renal Physiol. 2013 Dec 15;305(12):F1629-36
pubmed: 24107418
Lancet. 2016 Apr 9;387(10027):1513-1530
pubmed: 27061677
BMJ Open. 2018 Jan 10;8(1):e015069
pubmed: 29326180
Lancet. 2013 Jul 20;382(9888):260-72
pubmed: 23727169
Nephrol Dial Transplant. 2018 Oct 1;33(10):1812-1822
pubmed: 29342308
PLoS One. 2019 Aug 8;14(8):e0219377
pubmed: 31393877
BMC Med Res Methodol. 2012 Oct 11;12:156
pubmed: 23058038
Ann Intern Med. 2013 Jun 4;158(11):825-30
pubmed: 23732715
PLoS One. 2016 Jun 15;11(6):e0157281
pubmed: 27304429
Nephrol Ther. 2010 Jul;6(4):232-9
pubmed: 20409770